Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Treatment Options for Hyperhidrosis: Botulinum Toxins and Oral Medications

Description

The transcript reviews treatment options for hyperhidrosis, focusing on botulinum toxin injections and oral medications. Botulinum toxin is FDA-approved for axillary sweating, while use in palms, scalp, face, groin, and other areas is off-label. The speaker emphasizes mapping sweat with a starch-iodine test, injecting at the dermal/subcutaneous junction, and distributing toxin evenly rather than focusing on a specific number of injection points. In the axilla, 50 units per side is typically effective, with benefit lasting around five to six months; side effects are usually mild, such as injection discomfort, bruising, or rarely perceived compensatory sweating. For palmar and craniofacial areas, injections can be more uncomfortable and may cause muscle weakness, so ice, pressure, and careful counseling are used. Frey’s syndrome and facial hyperhidrosis are highlighted as additional useful indications, with attention to nearby muscles and potential functional changes. The second major topic is systemic therapy, especially anticholinergics such as glycopyrrolate and oxybutynin, which are off-label but helpful when topical or localized treatments are insufficient. Glycopyrrolate is preferred because it is less likely to cross the blood-brain barrier; both drugs are started low and titrated slowly while monitoring for dry mouth, constipation, and other anticholinergic effects. Beta blockers are described as useful for event-related sweating, such as public speaking or interviews, and patients should do a trial dose at home to check for side effects. Overall, treatment is individualized based on sweating pattern, severity, lifestyle, and risk of adverse effects.

View more

Conclusions

Botulinum toxin is an effective treatment for hyperhidrosis, but its formal FDA approval is limited to axillary disease and most other uses are off-label.
Accurate localization of sweating with starch-iodine testing helps target injections and improve outcomes across body sites.
The main therapeutic goal is not complete dryness but a meaningful reduction in sweating that improves daily functioning and lowers HDSS scores.
For axillary hyperhidrosis, about 50 units per axilla appears to work as well as higher doses, with benefits typically lasting around five to six months.
Side effects of botulinum toxin injections are usually mild, with pain, bruising, and occasional subjective compensatory sweating being the main concerns.
Palmar, craniofacial, facial, and Frey syndrome hyperhidrosis can also respond to botulinum toxin, but dosing is more variable and muscle weakness becomes a greater concern in these areas.
Oral anticholinergics are useful for patients with multiple affected areas or inadequate control with focal treatments, but their use is limited by anticholinergic side effects.
Glycopyrrolate is generally preferred over oxybutynin because it is less likely to cross the blood-brain barrier and cause central nervous system effects.
Oral anticholinergic therapy should be started at low doses and titrated gradually while monitoring for dry mouth, constipation, urinary retention, and other adverse effects.
Beta blockers such as propranolol are best reserved for event-related or anxiety-triggered sweating rather than continuous hyperhidrosis.
Successful systemic treatment requires matching therapy to the patient’s lifestyle and risks, including caution in athletes, outdoor workers, children, and patients with cardiac or pulmonary disease.
Using focal treatments together with systemic therapy, tracking outcomes over time, and counseling patients carefully are key to optimizing hyperhidrosis management.

Lowe NJ, Glaser DA, Eadie N, et al. JAAD Apr;56(4):604-11, 2007.
Basic & Clinical Pharmacology, 9th edition. Katzung ed. McGraw-Hill.